Form 4: BridgeBio Pharma Director Charles J. Homcy Receives New Equity Awards

BridgeBio Pharma, Inc. Director Charles J. Homcy was granted 6,589 restricted stock units and options to purchase 8,425 shares of common stock on June 20, 2025, as part of the company's incentive plan.

Summary

• Charles J. Homcy, a Director of BridgeBio Pharma, Inc. (BBIO), reported new equity awards on June 20, 2025.
• He was granted 6,589 Restricted Stock Units (RSUs) at a price of $0. These RSUs represent a contingent right to receive one share of common stock per unit.
• He also received options to purchase 8,425 shares of common stock with an exercise price of $41.73 per share.
• Both the RSUs and stock options will vest one-third each year after June 20, 2025, with full vesting by June 20, 2028, contingent on his continued service on the board.
• Following these transactions, Mr. Homcy beneficially owns 1,236,674 shares of common stock directly and 8,425 stock options directly.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive sign of aligning interests and standard compensation practice, without any negative implications.

Positives

• The grant of equity awards aligns the director's interests with shareholders, incentivizing long-term performance.
• The awards are part of a standard incentive plan, indicating ongoing commitment to executive compensation best practices.

Risks

• Vesting of equity awards is subject to continued service, meaning the director must remain on the board to fully realize the value.
• The value of the stock options is dependent on the future market price of BridgeBio Pharma's common stock exceeding the exercise price of $41.73.

Future Outlook

The vesting schedule for the granted restricted stock units and stock options extends until June 20, 2028, indicating a long-term incentive structure tied to the director's continued service and the company's future performance.

Industry Context

The grant of equity awards to directors is a common practice in the biotechnology and pharmaceutical industry, aligning the interests of board members with long-term shareholder value creation. This type of compensation is standard for attracting and retaining experienced leadership in a highly competitive sector.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a standard form of equity compensation in the U.S. public company landscape, particularly within the biotech sector.
• While specific comparable companies or projects are not mentioned in this Form 4, such grants are typically benchmarked against peer groups to ensure competitive compensation packages for board members.
• The vesting schedule of three years is also a common practice to encourage long-term commitment.

Stakeholder Impact

• Shareholders: The grant of equity awards aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• Continued service of Charles J. Homcy on the BridgeBio Pharma, Inc. board of directors for full vesting of equity awards.
• Future vesting events for RSUs and stock options on June 20, 2026, June 20, 2027, and June 20, 2028.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Form 4, SEC filing, insider transaction, restricted stock units, stock options, equity compensation, director compensation, beneficial ownership